Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug426 | BRII-196 Wiki | 0.71 |
| drug726 | Cannabis, Medical Wiki | 0.71 |
| drug422 | BNT162b2 Wiki | 0.50 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D000070627 | Chronic Traumatic Encephalopathy NIH | 0.71 |
| D005879 | Tourette Syndrome NIH | 0.71 |
| D000690 | Amyotrophic Lateral Sclerosis NIH | 0.50 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D016472 | Motor Neuron Disease NIH | 0.50 |
| D001714 | Bipolar Disorder NIH | 0.50 |
| D012640 | Seizures NIH | 0.41 |
| D005356 | Fibromyalgia NIH | 0.35 |
| D001927 | Brain Diseases NIH | 0.35 |
| D010300 | Parkinsonian NIH | 0.27 |
| D015212 | Inflammatory Bowel Diseases NIH | 0.27 |
| D000070642 | Brain Injuries, Traumatic NIH | 0.25 |
| D003424 | Crohn Disease NIH | 0.22 |
| D001930 | Brain Injuries, NIH | 0.21 |
| D059350 | Chronic Pain NIH | 0.21 |
| D012598 | Scoliosi NIH | 0.20 |
| D009103 | Multiple Sclerosis NIH | 0.20 |
| D040921 | Stress Disorders, Traumatic NIH | 0.13 |
| D014947 | Wounds and Injuries NIH | 0.13 |
| D013313 | Stress Disorders, Post-Traumatic NIH | 0.12 |
| D004194 | Disease NIH | 0.11 |
| D013577 | Syndrome NIH | 0.07 |
| D003141 | Communicable Diseases NIH | 0.05 |
| D007239 | Infection NIH | 0.04 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.03 |
| D018352 | Coronavirus Infections NIH | 0.03 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0006802 | Abnormal anterior horn cell morphology HPO | 0.71 |
| HP:0007354 | Amyotrophic lateral sclerosis HPO | 0.71 |
| HP:0100754 | Mania HPO | 0.50 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001250 | Seizure HPO | 0.41 |
| HP:0001298 | Encephalopathy HPO | 0.35 |
| HP:0002037 | Inflammation of the large intestine HPO | 0.27 |
| HP:0012532 | Chronic pain HPO | 0.24 |
| HP:0100280 | Crohn's disease HPO | 0.22 |
Navigate: Correlations HPO
There are 2 clinical trials
This will be a multistate, multicenter clinical study to determine the efficacy and safety of medical cannabis for a wide variety of chronic medical conditions.
Description: Covid-19 infection rates in cannabis users will be compared to rates in the general population. Our online questionnaire responses will compare infection rates of cannabis users in this study against the Johns Hopkins University Coronavirus Research Center data (https://coronavirus.jhu.edu).
Measure: Prevention of COVID-19 Time: Five yearsDescription: Severity of persistent symptoms in cannabis users testing positive for active infection and/or antibodies will also be compared to the general population. Patients will answer the widely used FLU-PRO questionnaire, which asks about flu symptoms and severity, to capture diagnoses, symptoms, and medical interventions related to COVID-19. The data from cannabis user patients will be compared with national and international data surveys, such as the Covid Symptom Study (https://covid.joinzoe.com/us-2).
Measure: Treatment of COVID-19 Time: Five yearsDescription: The primary objective is to assess the efficacy and safety of medical cannabis as medicine for treatment of chronic pain and other chronic debilitating diseases. Pain will be measured by Brief Pain Inventory (BPI) numeric scale. Change from baseline in BPI will be assessed at 3-month intervals. For prospective associations between cannabis use and outcomes, use of a lagged mixed-effects models will examine temporal associations between cannabis use and pain severity, opioid sparing, and patient satisfaction. Data will be analyzed from baseline and the annual follow-up waves.
Measure: Treatment of Symptoms Time: Five yearsDescription: Secondary objectives include evaluating increases or decreases in quality of life, and increases or decreases in concomitant opioid use. Satisfaction with treatment will be measured by a Visual Analog Score (VAS). Change From baseline in Satisfaction with treatment measured by (VAS) be assessed at 3-month intervals.
Measure: Cannabis Impact on Quality of Life Time: Five yearsDescription: Tertiary objectives will examine preferences for routes of administration, and preferences for THC / CBD ratios. Categorical factors will be summarized using frequencies and percentages, while continuous measure distributions will be described using means, standard deviations, and quartiles of interest.
Measure: Cannabis Route and Dosing Time: Five yearsDescription: Incidence of Treatment-Related Adverse Events will be measured by Physician Global Assessment (PGA) numeric scale. Number of participants with Treatment-Related Adverse Events will be assessed by CTCAE v4.0.
Measure: Monitoring Adverse Events Time: Five yearsBackground: Sickle cell disease (SCD) is a chronic illness. It affects about 100,000 people in the United States. People with SCD have red blood cells that are sickle-shaped and impaired in their function. This results in a lifetime of complications that affect every organ system. People with SCD also are at greater risk for respiratory infections and lung problems. Researchers want to study how this population s stress, anxiety, fear, pain, sleep, and health care use are being affected by the COVID-19 pandemic. Objective: To study the extent and impact of life changes induced by the COVID-19 pandemic on people living with SCD in the U.S. Eligibility: People age 18 and older with SCD who live in the U.S. Design: Participants will complete a survey online. The questions will focus on the following: Medical history Mental and physical health Demographics Stress Resilience Health care use COVID-19 Beliefs about medical mistrust and participation in research. At the end of the survey, participants will be asked if they would like to take the survey again in the future. If they reply yes, then they will be contacted by the study team in 6 months to take the survey again. They may complete the survey again in 6 months, 12 months, and 18 months. The survey should take less than 40 minutes to complete. Participants data will be coded to protect their privacy. The coded data may be shared with other researchers.
Description: We will examine how theo COVID-19 pandemic impacts stress levels among individuals with sickle cell disease (SCD).
Measure: Stress Time: baseline, month 6, month 12, month 18Description: We will examine how the COVID-19 pandemic impacts anxiety levels among individuals with SCD.
Measure: Anxiety Time: baseline, month 6, month 12, month 18Description: This is an examination of questions relating to depression, which we will examine within our cohort.
Measure: Depressive symptomology Time: baseline, month 6, month 12, month 18Description: We will examine the association between clinical severity of SCD and an individual s response to the COVID-19 pandemic.
Measure: Pain episodes, and severity Time: baseline, month 6, month 12, month 18Description: We will investigate the impact of the COVID-19 pandemic on healthcare utilization for SCD individuals.
Measure: Healthcare utilization (primary care, emergency department, telehealth other) Time: baseline, month 6, month 12, month 18Description: We would like to explore how the attitudes about treatment and levels of trust will serve as mediating factors for the experiences of individuals with SCD during this pandemic.
Measure: Receptivity to future health recommendations and medical treatment(s). Time: baseline, month 6, month 12, month 18Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports